🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Newly diagnosed with MM? MASTER-2 addressed response adapted therapy with the perspective of finite treatment. Accruing fast! #mmsm

Innovative trial from the COMMIT group- accruing fast MCW Cancer Center Medical College of Wisconsin ! Proud to be a part of this great study!

SOC lead-in allowed 🤩 so patients diagnosed in the hospital who start emergent CyBorD are allowed to enroll! Plus various other initiatives to make sure the trial population matches our RW #MMsm population, including racially. Plus an amazing two-part scientific question!

Luciano J Costa CBCI UAB O'Neal Comprehensive Cancer Center Columbia University Raj Chakraborty Bhagirath Dholaria, MD Medical College of Wisconsin Binod Dhakal Natalie Callander Fred Hutch Cancer Center Rahul Banerjee, MD, FACP OHSU Knight Cancer Institute It’s a great trial! And patients love it 🙌🏼

It should be in every discussion of cure in MM.

Establishing MRD trajectories for NDMM as benchmark for deployment of T-cell redirection therapy | Blood Cancer Journal. Another COMMIT contribution ⁦Susan Bal⁩ ⁦Binod Dhakal⁩ ⁦Natalie Callander⁩ ⁦Smit Giri MD MHS⁩ #mmMRD nature.com/articles/s4140…

"Deus ao mar o perigo e o abismo deu, mas nele e que espelhou o ceu"- Fernando Pessoa

📢New paper alert in @BloodJournal We present BloodFlow, a method with an unprecedented sensitivity of 10-7 in myeloma. Another step towards meaningful assessment of #MRD in blood #mmsm Congrats Marta Carmen González Díaz-Cano PETHEMA Clínica Universidad de Navarra Cima Universidad de Navarra ashpublications.org/blood/article/…

The HealthTree Cure Hub registry: A patient-centered, multicenter approach to advancing multiple myeloma care - Jorge Arturo Hurtado Martínez et al. HealthTree Foundation #ASCO25 Abst e19569 meetings.asco.org/abstracts-pres… #mmsm

The IMWG's mission is simple — to conduct and accelerate leading multiple myeloma research and transform patient care for the better. Stay tuned for insights from the IMF's upcoming 2025 International Myeloma Working Group Summit! #IMFIMWG #NCRM25 #mmsm

ASCO #myeloma great panel discussing MRD in myeloma Ben Derman Luciano J Costa Rebecca Silbermann Neha Korde

MIDAS (👏). Of 24% patients POS at 10-6 after induction in arm A, only 8% became NEG without transplant, vs. 13%/27% with transplant. OR of 1.86 in favor of Transplant. Let's find better alternatives to transplant. Premature to dismiss it. #MMSM

And a new era of MRD-guided personalized therapy… NEJM IACH COMy IUCT Oncopole Congratulations Aurore Perrot nejm.org/doi/abs/10.105…

Luciano J Costa This may be a more helpful figure - the sankey diagram shows not a huge difference in loss of MRD negativity or deepening with or without ASCT.

🚨New from ASCO: MSK cellular therapist Dr. Heather Landau shared dramatic results from a phase 1 clinical trial showing that a chimeric antigen receptor (CAR) T cell therapy appears to be effective at stopping AL amyloidosis in patients. The treatment appears to be safe and to

Just out! New IMS/ IMWG Definition of High Risk Myeloma. Journal of Clinical Oncology #IMWG25 Myeloma Society International Myeloma Foundation Nikhil C. Munshi, MD marivi mateos Sagar Lonial MD Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Noopur Raje

Patients with standard risk MM treated with QUADs + ASCT, achieving S-MRD negativity and stopping therapy have <10% risk of progression or MRD resurgence in 4 years!